We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGN.WS
151
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$1.38M 0.08%
1,529,526
+75,886
+5% +$139K
DVAX
152
PUT
DELISTED
Dynavax Technologies
DVAX
$1.38M 0.08%
569
-25
-4% -$626
POZN
153
DELISTED
POZEN INC
POZN
$1.36M 0.08%
199,800
-200
-0.1% -$1.34K
NBIX icon
154
PUT
Neurocrine Biosciences
NBIX
$18.3B
$1.36M 0.08%
241
-1,026
-81% -$52.1K
FWP
155
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.33M 0.07%
10,000
– –
TNXP icon
156
CALL
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
CRDC
157
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.33M 0.07%
856,918
+328,799
+62% +$645K
CEMP
158
PUT
DELISTED
Cempra, Inc.
CEMP
$1.29M 0.07%
415
-667
-62% -$18.6K
VRTX icon
159
Vertex Pharmaceuticals
VRTX
$125B
$1.26M 0.07%
10,000
-20,000
-67% -$2.41M
OCRX
160
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.2M 0.07%
385,300
-41,244
-10% -$141K
SGMO
161
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.2M 0.07%
131,100
-304,125
-70% -$2.34M
TNXP icon
162
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
CEMP
163
CALL
DELISTED
Cempra, Inc.
CEMP
$1.17M 0.06%
376
-3,273
-90% -$91.1K
ANAC
164
PUT
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$1.13M 0.06%
100
– –
PTLA
165
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.12M 0.06%
218
+12
+6% +$582
SGMO
166
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.12M 0.06%
1,225
+1,010
+470% +$7.78K
NDRM
167
PUT
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.11M 0.06%
+651
New +$12.7K
VASC
168
DELISTED
Vascular Solutions Inc
VASC
$1.05M 0.06%
30,626
-6,670
-18% -$226K
ARCT icon
169
Arcturus Therapeutics
ARCT
$162M
$1.05M 0.06%
+23,929
New +$1.08M
CSBR icon
170
Champions Oncology
CSBR
$75.3M
$1.04M 0.06%
291,595
+122,198
+72% +$525K
SSKN
171
DELISTED
Strata Skin Sciences
SSKN
$1.02M 0.06%
18,236
+5,079
+39% +$290K
KITE
172
DELISTED
Kite Pharma, Inc.
KITE
$1.02M 0.06%
16,571
-120,528
-88% -$8.48M
WGBS
173
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.01M 0.06%
+276,215
New +$1.37M
ABEO icon
174
Abeona Therapeutics
ABEO
$343M
$1.01M 0.06%
12,000
-1,628
-12% -$163K
EXEL icon
175
CALL
Exelixis
EXEL
$14B
$1.01M 0.06%
1,783
– –
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.